Skip to content

Released Aug 9, 2022, before the open

10-Q filed Aug 9, 2022, 40 days after period end · 0001628280-22-021958

Q2 2022 · 10-Q
Revenue$4.49M+1,509.3% vs Q2 2021+14.5% vs Q1 2022
Net Income-$27.31MN/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.66N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$29,188,000N/M
Operating Cash Flowderived-$29,012,000N/M
Free Cash Flowderived-$29,376,000N/M
Margins · derived
Operating margin-650.1%+7687.2 pt vs Q2 2021
Net margin-608.3%+7675.2 pt vs Q2 2021

What the release said

The release

Same quarter

MetricQ2 2022Q2 2021Q2 2020
Revenue$4.49M$279.00K$0.00
Net Income-$27.31M-$23.11M-$15.72M
EPS Diluted-$0.66-$0.63-$2.90

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR